Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 5/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TRPC5 | Q9UL62 | 6/20 | 0.31 |
| ▸ | LGMN | Q99538 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6283304 | 1.00 | POLB (0.39) | POLBPABPC1CYP2C9GAACYP1A2 | |
| SCHEMBL6289497 | 0.86 | POLB (0.38) | POLBPABPC1CYP2C9GAACYP1A2 | |
| SCHEMBL6289499 | 0.86 | POLB (0.38) | POLBPABPC1CYP2C9GAACYP1A2 | |
| SCHEMBL6285561 | 0.86 | POLB (0.38) | POLBPABPC1CYP2C9GAACYP1A2 | |
| SCHEMBL6285558 | 0.86 | POLB (0.38) | POLBPABPC1CYP2C9GAACYP1A2 | |
| SCHEMBL6289989 | 0.85 | GAA (0.37) | POLBPABPC1CYP2C9GAACYP1A2 | |
| SCHEMBL6289984 | 0.85 | GAA (0.37) | POLBPABPC1CYP2C9GAACYP1A2 | |
| SCHEMBL6283348 | 0.83 | SHMT2 (0.43) | POLBPABPC1CYP2C9TNFHTT | |
| SCHEMBL6283352 | 0.83 | SHMT2 (0.43) | POLBPABPC1CYP2C9TNFHTT | |
| SCHEMBL681893 | 0.78 | TNF (0.34) | CYP1A2TNFTRPC5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050059685-A1 | Pyridopyrimidine compounds and their uses | CELL THERAPEUTICS, INC. (US) | 2005-03-17 | — | — | US | disclosed |
| US-6825180-B2 | CYTOKINE INTRACELLULAR SIGNALING INHIBITORS; ANTIINFLAMMATORY AGENTS | CELL THERAPEUTICS, INC. | 2004-11-30 | — | — | US | disclosed |
| US-20040023995-A1 | Pyridopyrimidine compounds and their uses | CELL THERAPEUTICS, INC. | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023995-A1 | Pyridopyrimidine compounds and their uses | PLPBP, MAVS, PDXK | POLB 1069/4885PABPC1 983/4885CYP2C9 4462/4885 |
| US-20050059685-A1 | Pyridopyrimidine compounds and their uses | PLPBP, MAVS, PDXK | POLB 1069/4885PABPC1 983/4885CYP2C9 4462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.